||EPS - Basic
||Market Cap (m)
|Pharmaceuticals & Biotechnology
Summit Corp Share Discussion Threads
Showing 38426 to 38448 of 38450 messages
|According to SRPT the $22m is likely at the back end of 2nd Q (so end June).|
|abergale .. indeed it's good to see the NASDAQ coming back up closer to the current AIM share price again ... perhaps anticipation of the next Sarepta $22 million payment due in?|
Aye it makes sort of sense as to your reply to my moan,
but what price does this country put on life when it becomes some sort of lottery with us older folk of hospitalisation ,re. operations or care,
It seems we are surplus to requirements now then...
on a better note,
the other side of the pond is showing some positive moments.
|Thanks football. Good to see Summit the focus but not so good to be considering moving the HQ out of the UK.... if only a back of the mind thought right now.
I've done some reading though and the good news is that the HMRC allow shares in ISA's from any world stock exchange on their recognised list. Obviously their list includes all the major exchanges so I guess it wont matter where they locate... US or Germany ?|
Bizarrely, antibiotics for the likes of C Diff don't have as much interest or potential to generate income for the big pharma companies, compared to something like Sarepta's Eteplirsen which sells at $300,000 per patient.
The irony for the human race is that no pharmaceutical company would be interested for example in pursuing recent Canadian research (with just a 74 people sample), that found fasting on a regular basis produces a great list of impressive data. There seemed to be major health benefits such as reducing cholesterol levels, diabetes and even incidents of cancer ... but who in their right minds would want to invest serious money in researching something without income at the end of it?
EDIT - So research into say the health benefits of fasting, is left to underfunded state run establishments who simply don't have the same resources as the huge multi-billion dollar corporations.|
I agree with your post re, Scotland and England on C.diff,
lost an uncle to it and myself feel put off by my waterworks op. that's pending.
don't want something I didn't have before I go into hospital.
I personally feel that C.diff is more important than the DMD,,to he majority of older folk waiting operations of any sort.gla lth's|
|Reported today - interesting para £960,000 to deploy in biopharma sector but where?
Port Erin Biopharma (LON:PEBI): Redemption for £1m
Market Cap: £1.5m; Current Price: 7p
Redemption of holding in the Magna Biopharma Income Fund for £1m
Port Erin Biopharma (PEBI) announced that it will redeem for cash its entire holding of 87,125.729 units in the Magna Biopharma Income Fund (MBIF).
Port Erin's holding in the MBIF was valued at £1,038,704 at 31 March 2017.
This follows the decision by the Magna Umbrella Fund plc to close the MBIF.
As a consequence, Port Erin will receive approximately £960,000 in cash which the Company intends to deploy in the biopharma sector.
NORTHLAND CAPITAL PARTNERS VIEW: A positive development for PEBI, generating c. £1m of cash which the group can redeploy into new investments. PEBI trades at a significant and unwarranted discount to NAV. With £1m of cash now at its disposal, this discount appears even less justified|
|Per Free-Money today on the other board:
The Annual General Meeting will be held at 11:00am BST on Tuesday, 18 July 2017 at the Milton Park Innovation Centre, 99 Park Drive, Abingdon, Oxfordshire, OX14 4RY, UK.
Interesting rumour on T/O regarding Sarepta boosting their share price. I guess Summit need PoC on EZD to become a T/O target themselves but obviously with the deal any take over of Sarepta impacts Summit. Interesting to watch how any valuation develops.... if it's not just a rumour.
|C. diff infections are causing havoc in hospitals in Scotland and England
GlobalData is the market leader in providing actionable insight into the healthcare industry. With market analysts in 18 countries around the world, along with a team of researchers and consultants, we can provide you with the reliable, in-depth industry information you need.
Between October 2015 and October 2016, the NHS in Scotland reported 1,150 cases of C. difficile, or C. diff, infections — enough patients to continuously occupy a 30-bed hospital for a year — amounting to staggering costs of more than $11.1m.
While the actual number of C. diff cases — caused by a bacterium that can infect the bowel and cause diarrhoea — is relatively low, it should be noted that the reoccurring nature of C. diff amounts to the majority of the cost, with over half of discharged patients being readmitted to hospital within six months.
For the first time, researchers have compared 3,304 patients with C. diff infections with 9,516 patients without infections in Scottish hospitals from 2010–2013.
The researchers determined that C. diff infections not only doubled the risk of death within the first two months, but caused death in nearly a third of all registered cases of C. diff, while survivors of the initial infections frequently suffered from reoccurring infections within six months.
Of the cured patients, nearly 14 percent suffered from recurrent C. diff infections within three months, and nearly 30 percent were readmitted to hospital within a year.
Scotland is not the only country suffering from recurrent C. diff infections.
A similar study found that 15–30 percent of all C. diff cases in England are due to recurrent infections.
However, there are three potential pipeline drugs which are designed for recurring C. diff infections that could improve the situation – Seres Thrapeutics’ SER-109, Rebiotix’s RBX-2660, and Summit Therapeutics’ redinilazole.
|"Drugmaker Sarepta’s Stock Could Double or More
Sarepta’s Duchenne muscular dystrophy drug could attract a deep-pocketed acquirer."
|See SRPT story about being potential target?
O/T Excellent news re French elections. Macon is a centrist with socialist leanings but means EU will survive. I know that might not suit everyone but the markets will like it. Add in a bit of Trump tax cuts.....|
|Hi FreeMoney2 - Like your assessment & NASDAQ closed at £1.67 ( $1.28 to £)just below AIM.We do now need news to further support the share price & hoping for C-Diff deal Qtr2 or Qtr3 plus earlier DMD news.Hopefully share price has now bottomed.|
|Majority looks like back to back account transfers to me (e.g. Bed & ISA's)
These are usually executed near the bid price.
SP seems to have found a support level here... maybe a bounce soon or maybe we need news to break this level GLA|
|However odd the NASDAQ seems sometimes ... it at least seems to make some general representational sense. You see a buy and the graph moves up ... then a sell and it moves down.
AIM is so difficult to ever interpret.
HAPPY POETS DAY ALL!
|Most can be discounted as rollovers with the last as a partial repurchase, IMO.|
|Hi HM & tightest - It does look very odd but just been quoted 173.90 to Buy 5,000 shares which is also odd.|
|HM,Looks like a fair amount of stock being soaked-up today - what do they know that we don't! Filling an order, or something more interesting.......|
|Those pesky MMs ... I'd say 60,000 k shares look like sells and zero buys ... but still the share price hangs at 175p. AIM is a quirky beast.
EDIT - it just got quirkier with an share price rising to 177.5p with no apparent buys today - ?|
|Yes. Gold dust|
|Does inverted Head And Shoulders actually cause dandruff instead of curing it?|
|Getting close to inverted head and shoulders. Take off soon?|